Catching Cancer Early
The accessibility of next-generation sequencing (NGS), new clinical guidelines on the role OBGYN care providers play in identifying and managing women with hereditary breast and ovarian cancer syndrome, and evolving practice business needs have led to an increasing importance and application of inherited cancer predisposition testing.
Join the live conversation with Dr. Matthew Lederman, a reproductive endocrinologist and infertility specialist from RMA of New York, Dr. Elizabeth Etkin-Kramer, Associate Professor in OBGYN at FIU Herbert Wertheim College of Medicine, and Jill Chisholm, President and Founder of GeneScreen and Chief Medical Officer of Synergenomics, on the various considerations for, and the importance of, identifying those at risk for inherited cancer syndromes and how that necessitates updates to clinical management.
Among other things, our 45-minute discussion, moderated by Michelle Zimmerman, SVP & GM, Oncology Solutions at Sema4, will cover:
• Assessing risk through patient-provider engagement;
• Integrating programs to complement protocols; and
• Delivering results into physicians' workflows to improve patient outcomes.